Council of Scientific and Industrial Research

Annalakshmi Chinniah

Pratap Kumar Das

Suchandra Goswami

Janaswamy Madhusudana Rao

Suresh Babu Katragadda

Paruchuri Gangadhar Rao

Sukdeb Banerjee

Niranjan Prasad Sahu

Romesh Chandra Boruah

Moyurima Borthakur

Madan Gopal Barthakur

Sudip Kumar Kar

Nilendu Panda

Basudeb Achari

The present invention relates to flavanoid compounds of general formula (X) wherein: Ris selected from a group consisting of morpholinyl, N-methyl piperizinyl, piperidinyl and N,N'-dimethylamino groups, and n ranges from 3 to 6, and process for preparation thereof. The present invention relates to the demonstration of antiactivity and gastric antisecretory activity of semisynthetically designed flavonoid compounds, to be used for the prevention and treatment of gastroduodenal disorders in general and peptic ulcer diseases in particular. The present invention also relates to a hetero-dimeric bi-functional molecule that can be used as monotherapy substituting/replacing/overcoming currently used triple/quadruple therapy, thereby implicating/anticipating/envisaging its commercial applicability.

Flavanoid compounds and process for preparation thereof

The present invention relates to flavanoid compounds of general formula (X) wherein: Ris selected from a group consisting of morpholinyl, N-methyl piperizinyl, piperidinyl and N,N'-dimethylamino groups, and n ranges from 3 to 6, and process for preparation thereof. The present invention relates to the demonstration of antiactivity and gastric antisecretory activity of semisynthetically designed flavonoid compounds, to be used for the prevention and treatment of gastroduodenal disorders in general and peptic ulcer diseases in particular. The present invention also relates to a hetero-dimeric bi-functional molecule that can be used as monotherapy substituting/replacing/overcoming currently used triple/quadruple therapy, thereby implicating/anticipating/envisaging its commercial applicability. 

Flavonoid compounds and process for preparation thereof

The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2'-chloro-5-androsteno[17,16-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole, a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an ICvalue comparable to cimetidine. No mortality or behavioral abnormality of Swiss albino mice was observed under single-dose level of 1 g/Kg body weight of compound (4). Compound (4) further exhibited excellent anti ulcer activity in vivo against indomethacin induced ulcer.

Simultaneous method for the preparation of a mixture of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene and 3-acetoxy-2'-chloro-5-androsteno[17,16-b]pyridine

The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plantoptionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer diseases in a subject using the said pharmaceutical composition. It also relates to the use of the compound oenothein C in the treatment of peptic ulcer related diseases and a process for the isolation of the said compound.

Pharmaceutical composition useful for the treatment of peptic ulcer diseases

Growing community of inventors

Kolkata, India

Annalakshmi Chinniah